Received: 29 April 2020
Accepted: 24 June 2020
First Online: 3 July 2020
Ethics approval and consent to participate
: Prior to analysis the samples were de-identified. The Translational Research Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital (NKI-AVL) approved the use of patient material in this study.
: Not applicable.
: The authors have no competing interests for this work. KS is Genentech employee and holder of Roche stock. KM received personal fees from Roche, Pfizer, BMS, Abbvie, AstraZeneca, grants from AstraZeneca, non-financial support from Roche, non-financial support from Genentech outside the submitted work. SW is medical advisor for and/or receives research grants from Roche, Pfizer, MDS, AstraZeneca, Cergentis, Merck. MH received personal fees from Roche, Pfizer, BMS, MSD, BI, Novartis, AstraZeneca, grants from Roche, Pfizer, BMS, MSD, AstraZeneca, Novartis.